Published in Dtsch Med Wochenschr on February 03, 2006
Chemosensitivity of conjunctival melanoma cell lines to target-specific chemotherapeutic agents. Graefes Arch Clin Exp Ophthalmol (2012) 1.42
Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. Br J Cancer (2012) 1.90
Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol (2002) 1.68
Pharmacokinetic disposition of quinolones in human body fluids and tissues. Clin Pharmacokinet (1989) 1.67
Cardiac troponin I plasma levels for diagnosis and quantitation of perioperative myocardial damage in patients undergoing coronary artery bypass surgery. Eur J Cardiothorac Surg (1998) 1.46
Gastrointestinal secretion of ciprofloxacin. Evaluation of the charcoal model for investigations in healthy volunteers. Am J Med (1989) 1.41
The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie (2002) 1.39
Risk factors for venous thromboembolic events in cancer patients. Ann Oncol (2005) 1.32
Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur J Clin Pharmacol (2007) 1.14
An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer. Ann Oncol (2009) 1.12
Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors. Int J Clin Pharmacol Ther (2002) 1.11
Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann Oncol (2006) 1.10
Phase I clinical and pharmacokinetic study of titanocene dichloride in adults with advanced solid tumors. Clin Cancer Res (1998) 1.09
[Chemotherapy in advanced sarcomas (author's transl)]. Dtsch Med Wochenschr (1981) 1.07
Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours. Br J Cancer (2008) 1.06
Pharmacokinetic/pharmacodynamic modeling of biomarker response to sunitinib in healthy volunteers. Clin Pharmacol Ther (2010) 1.06
Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology (2005) 0.98
Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. Invest New Drugs (2010) 0.98
Etoposide and etoposide-ifosfamide therapy for refractory testicular tumors. Cancer Treat Rev (1982) 0.97
Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters. Pediatr Blood Cancer (2006) 0.95
Early results from a phase I study on orally administered tris(8-quinolinolato)gallium(III) (FFC11, KP46) in patients with solid tumors--a CESAR study (Central European Society for Anticancer Drug Research--EWIV). Int J Clin Pharmacol Ther (2005) 0.94
Oxaliplatin-DNA adduct formation in white blood cells of cancer patients. Br J Cancer (2008) 0.94
Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer. J Clin Oncol (2002) 0.93
Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan. Clin Pharmacol Ther (2010) 0.92
Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone Marrow Transplant (2005) 0.92
Marked elevation in homocysteine and homocysteine sulfinic acid in the cerebrospinal fluid of lymphoma patients receiving intensive treatment with methotrexate. Int J Clin Pharmacol Ther (2007) 0.92
Feasibility of intraventricular administration of etoposide in patients with metastatic brain tumours. Br J Cancer (2001) 0.89
Chemotherapy of metastatic seminoma. Br J Cancer (1985) 0.86
Determination of platinum complexes in clinical samples by a rapid flameless atomic absorption spectrometry assay. Ther Drug Monit (1999) 0.86
A phase I clinical and pharmacokinetic study of the camptothecin glycoconjugate, BAY 38-3441, as a daily infusion in patients with advanced solid tumors. Ann Oncol (2004) 0.85
The neu-oncogene product in serum and tissue of patients with breast carcinoma. Ann Oncol (1993) 0.84
Pharmacokinetics (PK) of a liposomal encapsulated fraction containing doxorubicin and of doxorubicin released from the liposomal capsule after intravenous infusion of Caelyx/Doxil. Int J Clin Pharmacol Ther (2005) 0.84
A preliminary report of a Phase II study of folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus sunitinib with toxicity, efficacy, pharmacokinetics, biomarker, imaging data in patients with colorectal cancer with liver metastases as 1st line treatment. Int J Clin Pharmacol Ther (2011) 0.83
Bioequivalence investigation of high-dose etoposide and etoposide phosphate in lymphoma patients. Cancer Chemother Pharmacol (2001) 0.83
Plasma and tissue pharmacokinetics of epirubicin and Paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer. Clin Pharmacol Ther (2007) 0.83
Investigation of bioavailability and pharmacokinetics of treosulfan capsules in patients with relapsed ovarian cancer. Cancer Chemother Pharmacol (2000) 0.83
In vitro and in vivo transport of zidovudine (AZT) across the blood-brain barrier and the effect of transport inhibitors. Pharm Res (1994) 0.82
Influence of the hOCT2 inhibitor cimetidine on the cellular accumulation and cytotoxicity of oxaliplatin. Int J Clin Pharmacol Ther (2009) 0.82
Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysis. Int J Clin Pharmacol Ther (2009) 0.82
Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006. Int J Clin Pharmacol Ther (2003) 0.82
Considerable plasma levels of a cytotoxic etoposide metabolite in patients undergoing high-dose chemotherapy. Eur J Cancer (1997) 0.82
Oxygen radical formation and DNA damage due to enzymatic reduction of bleomycin-Fe(III). Arch Toxicol (1987) 0.81
High-dose chemotherapy with autologous stem cell transplantation in patients with oligometastatic breast cancer. Bone Marrow Transplant (2004) 0.81
Correlation of ERK-phosphorylation and toxicities in patients treated with the Raf kinase inhibitor BAY 43-9006. Int J Clin Pharmacol Ther (2004) 0.81
Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: results of a clinical phase II-study with 151 patients. Cancer Treat Rev (1983) 0.81
Long-term survival after induction therapy with idarubicin and cytosine arabinoside for de novo acute myeloid leukemia. Ann Hematol (2000) 0.80
Plasma and cellular pharmacokinetics of doxorubicin after intravenous infusion of Caelyx/Doxil in patients with hematological tumors. Int J Clin Pharmacol Ther (2009) 0.80
Lack of neuroprotection by an ACTH (4-9) analogue. A randomized trial in patients treated with vincristine for Hodgkin's or non-Hodgkin's lymphoma. J Cancer Res Clin Oncol (2004) 0.80
Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. Int J Clin Pharmacol Ther (2010) 0.80
Pharmacokinetic study of S-1. Int J Clin Pharmacol Ther (2009) 0.80
Activity of N-benzyl-adriamycin-14-valerate (AD198), a new anthracycline derivate, in multidrug resistant human ovarian and breast carcinoma cell lines. Anticancer Drugs (1995) 0.80
Chronic myelogenous leukemia: effect of interferon-alpha treatment on phagocytic activity and capacity of circulating neutrophils. Leuk Res (1998) 0.79
Monitoring of patients with nonseminomatous testicular cancer by nuclear magnetic resonance spectroscopy of plasma. Eur J Cancer Clin Oncol (1989) 0.79
[The toxic shock syndrome in male patients]. Dtsch Med Wochenschr (1983) 0.79
Determination of the cytotoxic catechol metabolite of etoposide (3'O-demethyletoposide) in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl (1997) 0.79
Sequential combination chemotherapy with vinblastine-bleomycin and doxorubicin-cis-dichlorodiammineplatinum(II) in disseminated nonseminomatous testicular cancer. Cancer Treat Rep (1981) 0.79
Assessment of platinum sensitivity in human tumor cells. Int J Clin Pharmacol Ther (2003) 0.79
Separation and identification of platinum adducts with DNA nucleotides by capillary zone electrophoresis and capillary zone electrophoresis coupled to mass spectrometry. Electrophoresis (2001) 0.78
High-dose chemotherapy with peripheral blood stem cell transplantation for patients with advanced ovarian cancer. J Cancer Res Clin Oncol (2001) 0.78
Covalent protein binding of reactive adriamycin metabolites in rat liver and rat heart microsomes. J Cancer Res Clin Oncol (1982) 0.78
Prevention of adriamycin cardiotoxicity by niacin, isocitrate or N-acetyl-cysteine in mice. A morphological study. Pathol Res Pract (1986) 0.78
Utility of isotachophoresis-capillary zone electrophoresis, mass spectrometry and high-performance size-exclusion chromatography for monitoring of interleukin-6 dimer formation. J Chromatogr A (1999) 0.78
Individualised dosing strategy for high-dose carboplatin in patients with germ cell cancer. Br J Cancer (2003) 0.78
Biomarker response on exposure to sunitinib and its primary metabolite (SU12662) in metastatic colorectal cancer patients. Int J Clin Pharmacol Ther (2011) 0.78
Five-day continuous infusion of 5-fluorouracil and pulsed folinic acid in patients with metastatic colorectal carcinoma: an effective second-line regimen. Ann Oncol (1997) 0.78
ERK1/2 phosphorylation: a biomarker analysis within a phase I study with the new Raf kinase inhibitor BAY43-9006. Int J Clin Pharmacol Ther (2002) 0.78
Potential of on-line isotachophoresis-capillary zone electrophoresis with hydrodynamic counterflow in the analysis of various basic proteins and recombinant human interleukin-3. J Chromatogr A (1996) 0.78
Chemosensitivity of conjunctival melanoma cell lines to chemotherapeutic agents. Int J Clin Pharmacol Ther (2011) 0.77
A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors. Int J Clin Pharmacol Ther (2003) 0.77
Defining the role of MRP-mediated efflux and glutathione in detoxification of oxaliplatin. Pharmazie (2013) 0.77
Clinical pharmacokinetics of intravenous treosulfan in patients with advanced solid tumors. Cancer Chemother Pharmacol (1998) 0.77
Ultratrace voltammetric determination of DNA-bound platinum in patients after administration of oxaliplatin. Anal Bioanal Chem (2004) 0.77
Efficacy of ifosfamide, dacarbazine, doxorubicin and cisplatin in human sarcoma xenografts. Br J Cancer (1994) 0.77
Drug- and radiation-induced resistance in a human neurogenic sarcoma xenografted in nude mice. Cancer Chemother Pharmacol (1993) 0.77
Development and application of a simple assay to quantify cellular adducts of platinum complexes with DNA. Pharm Res (1999) 0.77
A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer. Breast Cancer Res Treat (2013) 0.76
Tissue toxicity of doxorubicin in first and second hyperthermic isolated limb perfusion--an experimental study in dogs. Eur J Surg Oncol (1997) 0.76
Pharmacokinetic and pharmacodynamic comparison of two doses of calcium folinate combined with continuous fluorouracil infusion in patients with advanced colorectal cancer. Pharm World Sci (1999) 0.76
Treatment of refractory malignant lymphomas with ifosfamide/etoposide combination chemotherapy. Cancer Treat Rev (1983) 0.76
In vitro effect of multidrug resistance modifiers on idarubicinol efflux in blasts of acute myeloid leukemia. J Cancer Res Clin Oncol (2000) 0.76
Pharmacokinetics of treosulfan in a myeloablative combination with cyclophosphamide prior to allogeneic hematopoietic stem cell transplantation. Int J Clin Pharmacol Ther (2004) 0.76
First-line treatment of patients with metastatic pancreatic cancer: results of a Phase II trial with S-1 (CESAR-Study group). Int J Clin Pharmacol Ther (2010) 0.76
[Raynaud's phenomenon following combined cytostatic treatment of malignant testicular tumours]. Dtsch Med Wochenschr (1982) 0.76
Pharmacokinetic study of sodium trans[tetrachlorobis(1H-indazole)-ruthenate (III)]/-indazole hydrochloride (1:1.1) (FFC14A) in patients with solid tumors. Int J Clin Pharmacol Ther (2009) 0.76
Population pharmacokinetics of cyclophosphamide, doxorubicin and etoposide in 30 patients with BEACOPP chemotherapy. Int J Clin Pharmacol Ther (2002) 0.76
Liver nuclear NADPH-cytochrome P-450 reductase may be involved in redox cycling of bleomycin-Fe(III), oxy radical formation and DNA damage. Free Radic Res Commun (1987) 0.76
Ifosfamide in combination chemotherapy for sarcomas and testicular carcinomas. Cancer Treat Rev (1983) 0.75
Phase II study of high-dose medroxyprogesterone acetate in advanced malignant melanoma. Br J Cancer (1989) 0.75
[The clinical and pharmacokinetic results of intrapleural epirubicin application]. Strahlenther Onkol (1997) 0.75
A phase-II study with idarubicin, ifosfamide and VP-16 (IIVP-16) in patients with refractory or relapsed aggressive and high grade non-Hodgkin's lymphoma. Leuk Lymphoma (1997) 0.75
Phase I and pharmacokinetic study of the P-glycoprotein modulator dexniguldipine-HCL. Eur J Med Res (1997) 0.75
Simultaneous measurement of cellular P-glycoprotein content and function by multiparametric flow-cytometry. Int J Clin Pharmacol Ther (2000) 0.75
[Value of tumor-associated antigens CA 72-4 vs. CEA and CA 19-9 in the follow-up after stomach cancer]. Dtsch Med Wochenschr (1998) 0.75
Does the multidrug-resistance modulator cyclosporin A increase the cardiotoxicity of high-dose anthracycline chemotherapy? Acta Oncol (1997) 0.75